Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay052021	Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress IND Application Allowed by FDA for FT538 in Solid Tumors; Clinical Trial to Commence in 2021 Phase 1 Data from FT516 and FT538 Programs in Relapsed / Refractory Acute Myeloid Leukemia to be Featured at Investor Event on May 13 New Data from FT516 Phase 1 Study in Relapsed / Refractory Lymphoma to Read All »	View HTML
Toggle SummaryMay042022	Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 FT819 Enrollment Ongoing in Single- and Multi-dose Cohorts for R/R BCL in Landmark Study of Off-the-shelf, iPSC-derived Read All »	View HTML
Toggle SummaryMay032023	Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma FT576 BCMA-targeted CAR NK Cell Program Accruing Patients in Multi-dose Escalation Read All »	View HTML
Toggle SummaryMar162017	Fate Therapeutics Reports Fourth Quarter 2016 Financial Results First Subject Treated with ProTmune™ for GvHD Prevention IND Cleared by FDA for FATE-NK100 Natural Killer Cell Product Candidate in AML First-of-Kind Cancer Immunotherapy Derived from Engineered Pluripotent Cell Line to Begin Clinical Translation iPSC-derived NK Cell Research Collaboration Read All »	View HTML Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 38.3 KB
Toggle SummaryMar022020	Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerability of Multi-dose Treatment Paradigm for Off-the-shelf, iPSC-derived NK Cells First Patients Treated with FT516, the First-ever Engineered iPSC-derived Cellular Immunotherapy, for AML Read All »	View HTML
Toggle SummaryFeb242021	Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Response Achieved, Read All »	View HTML
Toggle SummaryMar172014	Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Phase 2 PUMA Study of PROHEMA® Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA ® in Lysosomal Storage Disorders to Begin in 2H14 Encouraging Clinical Data Published Highlighting the Potential of Ex Vivo T Cell Modulation SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results 84.4 KB
Toggle SummaryMar032016	Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Data Updates for All Preclinical Adoptive Immunotherapy Programs Expected in 1H16 SAN DIEGO, Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results 38.1 KB
Toggle SummaryMar052018	Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated Read All »	View HTML
Toggle SummaryMar052019	Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States $201 Million in Cash & Short-term Investments as of December 31, 2018 SAN DIEGO , March 05, 2019 (GLOBE Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.